Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Myriberine A in preparation of acute gout treatment drug

A technology for acute gout and medicine, which is applied in the application field of Myriberine A in the preparation of medicine for treating acute gout, can solve the problems of granulocytopenia, aplastic anemia and the like, and achieves the effect of strong prevention and treatment activity and outstanding substantive characteristics.

Inactive Publication Date: 2013-09-11
李正梅
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although they have fast anti-inflammatory and analgesic effects, their toxic and side effects are also quite obvious. For example, the effective dose of colchicine is similar to the dose that produces diarrhea and other gastrointestinal symptoms. Absolutely contraindicated in the case of bleeding, and the administration of phenylbutazone for as short as 3 weeks can also cause severe neutropenia or aplastic anemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Myriberine A in preparation of acute gout treatment drug
  • Application of Myriberine A in preparation of acute gout treatment drug
  • Application of Myriberine A in preparation of acute gout treatment drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Embodiment 1: the preparation of compound Myriberine A tablet involved in the present invention:

[0018] Take 5 grams of compound Myriberine A, add 195 grams of dextrin, mix well, and make 1000 tablets with a conventional tablet machine.

Embodiment 2

[0019] Embodiment 2: the preparation of the compound Myriberine A capsule involved in the present invention:

[0020] Get 5 grams of compound Myriberine A, add 195 grams of starch, mix well, and make 1000 capsules.

[0021] The following pharmacodynamic experiments will further illustrate its drug activity.

experiment example 1

[0022] Experimental example 1: Myriberine A anti-acute gout inflammation experiment:

[0023] 1: method

[0024] ① Solution preparation

[0025] Add 5g of uric acid and 1000ml of distilled water to boil, add 5% NaOH solution to adjust the pH to 7.4, stir, cool and crystallize to make sodium urate crystals (MSU). The prepared MSU 10 mg was autoclaved, added 10 ml of serum-free DMEM culture solution, and ground to form a 1 mg / ml DMEM solution. During the experiment, this solution was added with DMEM culture medium to form MSU solutions with different concentrations of DMEM.

[0026] Myriberine A2.5mg, dissolved in dimethyl sulfoxide (DMSO), the final concentration of DMSO <0.02%, plus serum-free DMEM culture medium, prepared to a concentration of 2.5ug / ml, 25ug / ml, 250ug / ml.

[0027] Positive drug indomethacin 2.0mg, the method is the same as Myriberine A, the preparation concentration is 20ug / ml.

[0028] ② In vitro culture of vascular endothelial cells

[0029] The HUVEC ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a new use of Myriberine A in medicine, specifically an application of the Myriberine A in preparation of an acute gout treatment drug. Experimental research results show that the Myriberine A provides a protection effect for an acute gout model with human vascular endothelial cell damage caused by urate, and can be provided for inhibiting ICAM-1 expression, such that the Myriberine A can be used for preparing the acute gout inflammation treatment drug. According to the present invention, the use of the Myriberine A in acute gout treatment drug preparation is firstly disclosed, the skeleton belongs to a completely-new skeleton type, acute gout prevention and treatment activity of the drug is strong, possibility that any revelation is provided by other compounds does not exist, the drug has prominent substantive characteristics, and significant progress is provided for acute gout prevention and treatment with the drug.

Description

technical field [0001] The present invention relates to a new application of compound Myriberine A, in particular to the application of Myriberine A in the preparation of medicines for treating acute gout. Background technique [0002] Gout, also known as gouty arthritis, is a disease caused by the disorder of purine metabolism in the body. It is manifested by excessive uric acid in the blood, and it is easy to cause urate (MSU) to crystallize in joints and other tissues. The acute attack of gout is due to the local neutrophil infiltration and inflammatory response caused by MSU deposited in the joints. [0003] Western medicine selects three kinds of medicines for use in the acute attack stage of gout: colchicine, non-steroidal anti-inflammatory drugs and corticosteroids. The mechanism of action of colchicine is to bind to the tubulin of neutrophils, thereby hindering the activity of granulocytes and inhibiting granulocyte infiltration. Non-steroidal anti-inflammatory dru...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/519A61P19/06
Inventor 不公告发明人
Owner 李正梅
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com